Marksans Pharma Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/w6p799gvba310um5qxz6s34d.pdf

Key Takeaways


Margin & Cost Structure

Jitendra Sharma: "We believe that this year the EBITDA margin pressure will continue and we are expecting the EBITDA in the range of 17% to 20%, the FY22 overall EBITDA was 17.4% and we expect the EBITDA to remain between 17% and 20% in this year."

US Generics & Pricing

Mark Saldanha: "The bottomline pressure is always going to be very strong input cost, but definitely the sales pressure, I mean in the sales point of view, we too see a growth happening year-on-year..."

International Markets & Dubai Acquisition

Mark Saldanha: "Dubai basically for us is a platform for distribution in the Middle East."

Capacity, API Strategy & CAPEX

Mark Saldanha: "2020, obviously API companies had crazy evaluations, so consummating or finding out the right partner was a bit difficult. Now that reality has seeped into 2021 and 22, we are still exploring that, nothing concrete has come onto that..."

Balance Sheet & Working Capital


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue target₹2,000 croresWithin 3 years
EBITDA margin17% to 20%FY23
Gross margin50% to 52%FY23
Effective tax rate22% to 24%FY23
R&D spendIncrease to 4%–5% of sales (from ~2% in FY22)Over next few years
Goa manufacturing lineStart productionEnd of calendar year 2022
API DMF filingsFile a few DMFs with own APIBy end of 2022
US product launches3 to 4 new launchesFY23
UK product filings8 products to fileFY23
Dubai acquisition revenueDouble acquired company's revenueWithin 2 years of taking charge
ReceivablesRemain around 90 days, no further increase expectedComing quarters
Warrant conversionBalance 75% money calledSometime in current year, or earlier if acquisition requires
DebtNo short-term debt; longer-term debt not beyond 1x EBITDAOngoing

Key Metrics

MetricQ4 FY22
Operating revenue₹418 cr, +26.6% YoY vs ₹330 cr
Gross profit₹206 cr, +1.5% YoY
Gross margin49.4%
EBITDA₹63.6 cr
Profit before tax₹52.6 cr
Profit after tax₹29.7 cr
Total depreciation charge₹21 cr, includes ₹12 cr one-time catch-up for Ind AS 116 lease accounting on US and UK warehouses
Finance cost₹5 cr, vs ₹1 cr in Q3 FY22 and ₹3 cr in Q4 FY21
FY22 revenue₹1,490 cr, +8.3% YoY
FY22 US / North America revenue₹635 cr, +8.5% YoY
FY22 EU & UK formulation revenue₹609 cr, +4.7% YoY
FY22 Australia / New Zealand formulation revenue₹179.8 cr, +22.9% YoY
FY22 EBITDA margin17.4%, vs 24.7% in FY21
FY22 PAT₹186.8 cr
FY22 EPS₹4.51
FY22 CAPEX₹46.3 cr
FY22 R&D spend₹30.2 cr, ~2% of sales; expected to increase to 4-5% of sales over next few years
Cash and cash equivalents₹349.3 cr
US price erosion (FY22)Single high-digit percentage
Product launches in Q43 new products in US, 12 in UK
Product pipeline>76 products total: 34 UK, 32 US (27 OTC, 5 RX), 10 Australia & New Zealand
UK pipeline detail8 products planned to file in FY23, 16 already filed and awaiting approval
Expected US launches in FY233 to 4 new launches
Average receivable days (FY22)~90 days
FY23 EBITDA margin guidance17% to 20%
FY23 gross margin guidance50% to 52%
FY23 effective tax rate guidance22% to 24%
Revenue target₹2,000 cr, expected within 3 years
Dubai acquisition cost1.3 cr AED, approximately ₹27-28 cr; existing revenue ~1.4 cr dirhams
Warrant issue₹93 cr, 25% received upfront, convertible within 18 months from 20 July 2021